Bicyclic(azaaromatic)indoles as inhibitors of leukotriene bisynthesis

A compound of the formula I:

• ##STR14## wherein:
• Het is ArR.sup.1 R.sup.2 R.sup.3 ;
• Ar is quinolinyl, the tetrahydro derivative thereof, and the N-oxide thereof;
• R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, and R.sup.11 are independently hydrogen, halogen, perhalo lower alkenyl, lower alkyl, lower alkenyl, lower alkynyl, --CF.sub.3, --CN, --NO.sub.2, --N.sub.3, --C(OH)R.sup.12 R--S(O).sub.2 R.sup.15, --S(O).sub.2 NR.sup.16 R.sup.16, --OR.sup.16, --NR.sup.16 R.sup.16, --NR.sup.13 CONR.sup.16 R.sup.16, --COR.sup.17, CONR.sup.16 R.sup.16, or --(CH.sub.2).sub.t R.sup.22 ;
• R.sup.6 is hydrogen, --CH.sub.3, CF.sub.3, --C(O)H, X.sup.1 --R.sup.7 or X.sup.2 --R.sup.8 ;
• R.sup.7 and R.sup.10 are independently alkyl, alkenyl, --(CH.sub.2).sub.u Ph(R.sup.11).sub.2 or --(CH.sub.2).sub.u Th(R.sup.11).sub.2 ;
• R.sup.8 is --CF.sub.3 or R.sup.7 ;
• R.sup.9 is hydrogen or X.sup.3 --R.sup.10 ;
• each R.sup.12 is independently hydrogen or lower alkyl, or two R.sup.12 's on same carbon atom are joined to form a cycloalkyl ring of 3 to 6 carbon atoms;
• R.sup.13 is hydrogen, lower alkyl or --CH.sub.2 R.sup.22 ;
• R.sup.14 is lower alkyl or --(CH.sub.2).sub.r R.sup.22 ;
• R.sup.15 is --CF.sub.3 or R.sup.14 ;
• R.sup.16 is hydrogen, OH, --COR.sup.17, R.sup.14, or two R.sup.16 's on the same nitrogen may be joined to form a monocyclic heterocyclic ring of 4 to 6 atoms containing one N;
• R.sup.17 is hydrogen, --CF.sub.3, lower alkyl, lower alkenyl, lower alkynyl or --(CH.sub.2).sub.r R.sup.22 ;
• R.sup.18 is --(CH.sub.2).sub.s --C(R.sup.19 R.sup.19)--(CH.sub.2).sub.s --R.sup.20 or --CH.sub.2 CONR.sup.16 R.sup.16 ;
• R.sup.19 is hydrogen or lower alkyl;
• R.sup.20 is
• a) 2,5-dioxo-1-pyrrolidinyl, (3-pyridinylcarbonyl) amino, 1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl, 1,3-dihydro-2H-isoindol-2-yl, 2,4-imidazolinedion-1-yl, 2,6-piperidinedion-1-yl, 2-imidazolyl, 2-oxo-1,3-dioxolen-4-yl, piperidin-1-yl, morpholin-1-yl, or piperazin-1-yl, or
• b) the radical W-R.sup.21 ;
• R.sup.21 is alkyl or --COR.sup.24 ;
• R.sup.22 is phenyl substituted with 1 or 2 R.sup.23 groups;
• R.sup.23 is hydrogen, halogen, lower alkyl, lower alkoxy, lower alkylthio, lower alkylsulfonyl, lower alkylcarbonyl, --CF.sub.3, --CN, --NO.sub.2 or --N.sub.3 ;
• R.sup.24 is alkyl, cycloalkyl, or a monocyclic group of 5 to 7 members containing 1 heteroatom selected from N, S or O;
• R.sup.25 is the residual structure of a standard amino acid, or R.sup.19, R.sup.25 together with the N to which they are attached from a proline residue;
• R.sup.26 is hydrogen or lower alkyl;
• R.sup.27 is lower alkyl or R.sup.26 and R.sup.27 on the same carbon are joined to form a cycloalkyl ring of 3 to 6 carbon atoms;
• m is 1 to 3;
• n is 0 to 3;
• p is 1 to 3 when m is 1;
• p is 0 to 3 when m is 0;
• r is 0 to 2;
• s is 0 to 3;
• t is 0 to 2;
• u is 0 to 3;
• W is O, S or NR.sup.16
• X.sup.1 is O or NR.sup.16 ;
• X.sup.2 is CO, CR.sup.12 R.sup.12, S, S(O), or S(O).sub.2 ;
• X.sup.3 is CO, CR.sup.12 R.sup.12, S(O).sub.2, or a bond;
• X.sup.4 is CR.sup.26 .dbd.CR.sup.27, CR.sup.27 .dbd.R.sup.26, CR.sup.26 R.sup.27 Y.sup.1, or Y.sup.1 CR.sup.27 R.sup.26 ;
• Y is X.sup.1, X.sup.2, O--NR.sup.16, NR.sup.16 --O or a bond;
• Y.sup.1 is O, S, S(O).sub.2, or CR.sup.26 R.sup.26 ;
• Q is --CO.sub.2 R.sup.13, --CONHS(O).sub.2 R.sup.15, --NHS(O).sub.2 R.sup.15, CN,
• --S(O).sub.2 NHR.sup.16, --CONR.sup.16 R.sup.16, --CO.sub.2 R.sup.18, --CONR.sup.19 R.sup.25,
• --CR.sup.12 R.sup.12 OH, or 1H-- or 2H-tetrazol-5-yl, --NR.sup.16 R.sup.16,
• --NR.sup.16 CONR.sup.16 R.sup.16, --C(.dbd.NR.sup.16)R.sup.17, --NR.sup.16 (CH.sub.2).sub.m NR.sup.16 R.sup.16,
• --N(R.sup.16)(CH.sub.2).sub.m NR.sup.16 CONR.sup.16 R.sup.16, --CON(R.sup.16)(CH.sub.2).sub.m --
• NR.sup.16 R.sup.16, or --CON(R.sup.16 (CH.sub.2).sub.m NR.sup.16 CONR.sup.16 R.sup.16;
• or a pharmaceutically acceptable salt thereof.